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ABSTRACT Localized scleroderma is an uncommon disease, only in-
frequently encountered by dermatologists in private practices or even 
in larger academic centers. Because of its rarity, current treatment 
guidelines are mostly based on low-level clinical evidence and expert 
opinions. The aim of this study was to evaluate treatment strategies 
to treat localized scleroderma. A questionnaire was developed and 
sent to dermatologists in Hungary. 101 returned questionnaires were 
eligible for evaluation. 87.12% of clinicians employed local steroids. 
Antibiotics were the most preferred systemic agents. Penicillin was 
used by 32.67% and doxycycline by 22.77% of dermatologists. Metho-
trexate was employed by only 6.93%. Borrelia serology was obtained 
by 80.19% of clinicians. More than half of practitioners performed ex-
tractable nuclear antigen (ENA) screening (53.46%). Most Hungarian 
dermatologists did not follow current treatment recommendations for 
morphea, a trend that likely holds true for other dermatology prac-
tices in the East-Central European region as well. Easily accessible, evi-
dence-based guidelines are needed to improve patient care. Patients 
with localized scleroderma should be referred to specialized centers 
with more experience where high quality care can be ensured. 
KEY WORDS: morphea, treatment approaches, survey 
INTRODUCTION
Morphea is an uncommon disease which leads 
to fibrosis of the dermis, subcutaneous fat, or both. 
Because of its rarity and due to the lack of universally 
used standardized clinical and histological scale to 
assess severity, evidence-based therapies are lacking 
(1). Treatment of morphea continues to be challeng-
ing, often leaving both the patients and the treating 
physicians unsatisfied. Treatments are mostly based 
on low-quality clinical evidence including non-ran-
domized, uncontrolled clinical trials with only a lim-
ited number of patients. In Europe, infectious agents 
such as Borrelia burgdorferi are thought to be a pos-
sible contributor to the pathogenesis of morphea 
– in at least a subpopulation of patients – therefore 
antibiotics are often employed by dermatologists. Al-
though convincing efficacy data are lacking, topical 
corticosteroids are also frequently used to target the 
inflammatory aspect of the disease. Extensive forms 
of localized scleroderma are also commonly treated 
with various forms of light therapy, which have been 
shown to inhibit several key steps of fibrosis. 
The aim of this study was to evaluate the diagnos-
tic and therapeutic decisions of dermatologists in this 
challenging disease in Hungary and to compare our 
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findings with the currently available recommenda-
tions. 
METHODS
Based on the mailing list of the Hungarian Derma-
tology Society, 800 questionnaires were sent out to 
dermatologists working both in outpatient and inpa-
tient settings in Hungary. The questionnaire included 
questions concerning treatment and management of 
localized scleroderma. 
Treatment-specific questions were the following: 
use of topical agents (topical steroids class 1-2 and 
3-4, topical calcineurin inhibitors, emollients, other 
agents), use of light therapy (psoralen and ultraviolet 
A (PUVA), narrowband ultraviolet B (nbUVB), others), 
use of systemic antibiotics (doxycycline, clarithromy-
cin, azithromycin, penicillin, others), use of systemic 
immunosuppressive and immunomodulatory drugs 
(systemic steroids, methotrexate, cyclosporine, cyclo-
phosphamide, azathioprine, mycophenolate mofetil, 
tumor necrosis factor (TNF)-alpha inhibitors, ritux-
imab, etc.). Furthermore, practitioners were also re-
quested to rank their therapeutic choices into lines of 
therapy (first line, second line, third line).
Investigation-specific questions were as follows: 
dermatologists were asked to provide a list of fre-
quently ordered diagnostic tests such as histology, 
autoimmune serology, post infectious serology es-
pecially for Borrelia burgdorferi, Mycoplasma pneu-
moniae and cytomegalovirus, search for infectious 
foci, search for sexually transmitted infections (STI), 
etc. Dermatologists had to indicate how often they 
used these tests (often, rarely, or never). Dermatolo-
gists were asked how they determine the efficacy of 
treatment (photo documentation, palpation, severity 
scales such as body surface area (BSA), or a localized 
scleroderma cutaneous assessment tool (LoSCAT) as 
well as patient satisfaction, etc.). Furthermore, clini-
cians were asked what factors influence their intent 
to treat (presence of a concurrent infection, extent of 
disease) and if they use only antibiotics or only im-
munosuppressive drugs in the systemic treatment of 
morphea. 
Clinicians were also asked to estimate how many 
patients with morphea they treat each year and if they 
have an additional board-certification (allergology 
and clinical immunology, etc.) besides dermatology. 
Lastly, practitioners were also requested to provide 
the setting where they practice dermatology (univer-
sity department, hospital, private practice, etc.).
Statistical analysis
We used descriptive statistics. The statistical anal-
ysis and graphic illustration of the results were per-
formed using Microsoft® Excel® 2015 for Windows®.
RESULTS
Occupational data
An average of 6.75 patients with morphea were 
seen by dermatologists per year. 14.85% of the prac-
ticing dermatologists decided to refer patients with 
morphea to larger clinical centers. 
15.84% of the participants worked at a univer-
sity department, 18.81% at a hospital with inpatient 
dermatology, and the majority, 45.54%, in a private 
medical office.
11.88% of the specialists held dual board certifi-
cation in dermatology and allergy and clinical immu-
nology.
101 questionnaires were completed and returned 
to us. 
Topical therapy
Class 3-4 topical steroids were used most fre-
quently by dermatologist and were noted as first-line 
topical therapy (37.95%). Class 1-2 steroids were pre-
scribed by 26.27% as the first-line treatment. Derma-
tologists began to treat morphea with a topical cal-
cineurin inhibitor in 7.29% respondents. Emollients 
were recommended in 28.46% of the cases. Others 
agents included vitamin D3 analogues alone or in 
combination with bethamethasone valerate, urea, or 
ichthyol (Figure 1).   
Figure 1. Use of topical treatment (first line).
Light therapy
PUVA was employed as a 2nd line treatment in 
20.79% of the cases. NbUVB was ordered as a 1st line 
light therapy by 9.90% of respondents. Some derma-
tologists recommended bath PUVA, cream PUVA, and 
UVA treatment alone.  
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Use of antibiotics
Antibiotics were widely used by dermatologists 
in the treatment of morphea. More than half of the 
practitioners used antibiotics as a first-line treatment 
(Figure 2). One third of dermatologists prescribed 
penicillin (32.67%). The second most frequently 
prescribed antibiotic was doxycycline with 22.77%. 
Other antibiotics such as macrolides were used less 
frequently (4.95%).
concurrent infection was identified. 30.69% of practi-
tioners chose only antibiotics as systemic agents. Only 
4.95% exclusively used immunosuppressive drugs if a 
systemic therapy was required (Figure 4). 
Figure 5. Diagnostic tools and procedures.
Figure 2. Use of systemic antibiotics (1st, 2nd, 3rd line).
Use of immunosuppressive and immuno-
modulatory drugs
Immunosuppressive drugs were rarely prescribed 
(Figure 3). Systemic steroids were used as a first choice 
in 21.78% of respondents and relatively common as a 
3rd line therapy with 13.86% frequency. Methotrexate 
was used as a 1st line systemic agent only in 6.93% 
and more frequently as a 2nd line treatment by 12.87% 
of respondents. Cyclosporine was mentioned as a 3rd 
line agent. Other immunosuppressive drugs were 
used sporadically. 
Treatment decision 
91.08% of dermatologists noted that the extent 
of the disease is an important factor when choos-
ing treatment modality (91.08%). 71.28% answered 
that their treatment choice depended on whether a 
Figure 3. Use of immunosuppressive drugs (1st 2nd 3rd line).
Figure 4. Factors influencing therapeutic decision.
Controlling treatment efficacy
28.71% of the polled dermatologists reported em-
ploying photo documentation. 88.81% noted they 
palpate the plaques for signs of softening. 54.45% 
calculated BSA and 6.93% used LoSCAT to monitor 
disease progression.
Diagnostic tools and procedures
About half of dermatologists relied on histopa-
thology to diagnose morphea (50.49%). Search for 
infectious foci was also commonly recommended 
(57.42%). Borrelia burgdorferi serology was obtained 
by 80.19% respondents. Search for autoantibodies 
was recommended by 53.46% percent of physicians. 
Diagnostic tests for sexually transmitted infections 
were used in 10.89% of responses (Figure 5).
DISCUSSION
Little is known about how patients with mor-
phea are treated by dermatologists in East-Central 
Europe, including Hungary. In our survey, we found 
that dermatologists prefer antibiotics in the systemic 
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treatment of morphea. More than half of surveyed 
dermatologists chose penicillin or doxycycline if a 
systemic treatment was needed. The use of immuno-
suppressive drugs was surprisingly low. Methotrex-
ate (MTX) was ordered as a first line treatment by only 
6.93% of dermatologists. Systemic steroids were also 
used more frequently (21.78%). These results show 
that most of the dermatologists in Hungary do not 
follow the current international recommendations. 
Similar to the therapeutic strategies detailed 
above, our diagnostic approaches also seem to differ 
from current regional guidelines. Borrelia serology is 
almost routinely ordered (80.19%) by clinicians, even 
though this test is only recommended if there is a 
high degree of clinical suspicion to suggest Borrelia 
burgdorferi infection. More than half of practitioners 
perform ENA screening (53.46%). The actual guide-
lines recommend this procedure only if another auto-
immune disease is clinically suspected (1).
An official Hungarian morphea guideline does 
not exist. The European Dermatology Forum recently 
published the current S1-Guideline on the Diagnosis 
and Treatment of Sclerosing Diseases of the Skin (1). 
This work recommends the use of systemic steroids 
and MTX. The use of antibiotics is no longer recom-
mended. In the United States, a detailed continuing 
medical education paper discussed the treatment of 
morphea. The authors concluded that the best evi-
dence indicates the combination of steroids and MTX 
as well as UVA1 phototherapy for the treatment of 
severe morphea (2). Antibiotics are not mentioned in 
this paper either. 
In North America, one web-based survey inves-
tigated the treatment regimens used by pediatric 
rheumatologists to treat morphea in children. Most 
pediatric rheumatologists used a combination of 
MTX and corticosteroids. Topical medications were 
used only in limited forms (3). 
A cohort trial on morphea in adults and children 
revealed a large variation in treatment in the United 
States. Treatment strategies depended partially on the 
diagnosing specialty. While rheumatologists prefered 
systemic immunosuppressive drugs, dermatologists 
primarily prescribed local therapy and phototherapy. 
Topical steroids were prescribed by 40.72% derma-
tologist for morphea, and phototherapy is used by 
16.29%. Antibiotics as well as antimalarials were used 
by 7.17% of dermatologists and approximately twice 
as often by rheumatologists (14.12%) (4). 
A national survey of 155 clinicians in the United 
Kingdom revealed that all respondents recommend 
topical therapy (very potent and potent topical ste-
roids, vitamin D analogues, calcineurin inhibitors). 
PUVA was employed by 38%. Methotrexate was used 
alone by 25% of clinicians and by 37% in combination 
with steroids (5). 
CONCLUSION
The low prevalence of morphea provides limited 
opportunities for most dermatologists to gain suffi-
cient experience in treating this condition. According 
to our results, dermatologists only see 6.75 patients 
with morphea per year on average, and hence most 
have only limited experience in treating this patient 
population. In light of these numbers, it is some-
what surprising that only a fraction of dermatologists 
(14.85%) decided to refer patients with morphea to a 
larger university department. A better approach may 
be to identify clinical centers with specialists who 
have more experience in treating morphea and to 
consistently refer patients to these departments. This 
may facilitate the training of future specialists with 
expertise in treating localized scleroderma and may 
also provide enough patients to design larger clinical 
trials, advancing the field of translational morphea re-
search and ultimately benefiting this unique patient 
population. 
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